Emergent BioSolutions Inc. (0IGA.L)
USD 4.41
(-11.45%)
USD 4.41
(-11.45%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 446.5 Million USD | -0.45% |
| 2022 | 448.5 Million USD | -44.59% |
| 2021 | 809.4 Million USD | -3.76% |
| 2020 | 841 Million USD | 5.34% |
| 2019 | 798.4 Million USD | 1.77% |
| 2018 | 784.5 Million USD | 5729.68% |
| 2017 | 13.45 Million USD | -94.58% |
| 2016 | 248.09 Million USD | -1.94% |
| 2015 | 253 Million USD | 0.8% |
| 2014 | 251 Million USD | 304.84% |
| 2013 | 62 Million USD | 6.34% |
| 2012 | 58.3 Million USD | 7.78% |
| 2011 | 54.09 Million USD | 78.89% |
| 2010 | 30.23 Million USD | -32.69% |
| 2009 | 44.92 Million USD | 25.02% |
| 2008 | 35.93 Million USD | -15.62% |
| 2007 | 42.58 Million USD | 35.77% |
| 2006 | 31.36 Million USD | 198.69% |
| 2005 | 10.5 Million USD | -11.16% |
| 2004 | 11.82 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 447 Million USD | 0.07% |
| 2024 Q1 | 446.7 Million USD | 0.04% |
| 2023 Q2 | 448 Million USD | 0.07% |
| 2023 Q4 | 446.5 Million USD | -0.38% |
| 2023 FY | 446.5 Million USD | -0.45% |
| 2023 Q1 | 447.7 Million USD | -0.18% |
| 2023 Q3 | 448.2 Million USD | 0.04% |
| 2022 FY | 448.5 Million USD | -44.59% |
| 2022 Q4 | 448.5 Million USD | -56.54% |
| 2022 Q2 | 793.6 Million USD | -0.99% |
| 2022 Q3 | 1.03 Billion USD | 30.05% |
| 2022 Q1 | 801.5 Million USD | -0.98% |
| 2021 FY | 809.4 Million USD | -3.76% |
| 2021 Q1 | 833.1 Million USD | -0.94% |
| 2021 Q2 | 825.2 Million USD | -0.95% |
| 2021 Q3 | 817.3 Million USD | -0.96% |
| 2021 Q4 | 809.4 Million USD | -0.97% |
| 2020 Q1 | 762.9 Million USD | -4.45% |
| 2020 FY | 841 Million USD | 5.34% |
| 2020 Q4 | 841 Million USD | -0.88% |
| 2020 Q3 | 848.5 Million USD | 11.92% |
| 2020 Q2 | 758.1 Million USD | -0.63% |
| 2019 Q3 | 813.3 Million USD | -2.06% |
| 2019 Q4 | 798.4 Million USD | -1.83% |
| 2019 Q2 | 830.4 Million USD | 13.38% |
| 2019 FY | 798.4 Million USD | 1.77% |
| 2019 Q1 | 732.4 Million USD | -6.64% |
| 2018 Q2 | 13.48 Million USD | 0.1% |
| 2018 Q1 | 13.46 Million USD | 0.09% |
| 2018 FY | 784.5 Million USD | 5729.68% |
| 2018 Q3 | 13.49 Million USD | 0.1% |
| 2018 Q4 | 784.5 Million USD | 5713.26% |
| 2017 FY | 13.45 Million USD | -94.58% |
| 2017 Q4 | 13.45 Million USD | -94.6% |
| 2017 Q3 | 248.99 Million USD | 0.12% |
| 2017 Q2 | 248.69 Million USD | 0.12% |
| 2017 Q1 | 248.39 Million USD | 0.12% |
| 2016 Q4 | 248.09 Million USD | 0.12% |
| 2016 FY | 248.09 Million USD | -1.94% |
| 2016 Q1 | 247.19 Million USD | -2.3% |
| 2016 Q2 | 247.39 Million USD | 0.08% |
| 2016 Q3 | 247.79 Million USD | 0.16% |
| 2015 Q3 | 253 Million USD | 0.0% |
| 2015 Q1 | 251 Million USD | 0.0% |
| 2015 Q4 | 253 Million USD | 0.0% |
| 2015 FY | 253 Million USD | 0.8% |
| 2015 Q2 | 253 Million USD | 0.8% |
| 2014 Q2 | 251 Million USD | 0.0% |
| 2014 Q1 | 251 Million USD | 304.84% |
| 2014 FY | 251 Million USD | 304.84% |
| 2014 Q4 | 251 Million USD | 0.0% |
| 2014 Q3 | 251 Million USD | 0.0% |
| 2013 Q4 | 62 Million USD | 12.83% |
| 2013 Q1 | 57.18 Million USD | -1.92% |
| 2013 Q2 | 56.06 Million USD | -1.95% |
| 2013 FY | 62 Million USD | 6.34% |
| 2013 Q3 | 54.95 Million USD | -1.99% |
| 2012 FY | 58.3 Million USD | 7.78% |
| 2012 Q3 | 58.86 Million USD | 1.25% |
| 2012 Q2 | 58.14 Million USD | 0.95% |
| 2012 Q1 | 57.59 Million USD | 6.47% |
| 2012 Q4 | 58.3 Million USD | -0.95% |
| 2011 FY | 54.09 Million USD | 78.89% |
| 2011 Q4 | 54.09 Million USD | 10.68% |
| 2011 Q3 | 48.87 Million USD | 68.1% |
| 2011 Q2 | 29.07 Million USD | -1.97% |
| 2011 Q1 | 29.65 Million USD | -1.92% |
| 2010 Q4 | 30.23 Million USD | -16.52% |
| 2010 Q1 | 44.16 Million USD | -1.7% |
| 2010 Q2 | 36.91 Million USD | -16.43% |
| 2010 Q3 | 36.22 Million USD | -1.86% |
| 2010 FY | 30.23 Million USD | -32.69% |
| 2009 FY | 44.92 Million USD | 25.02% |
| 2009 Q4 | 44.92 Million USD | 119.16% |
| 2009 Q3 | 20.5 Million USD | -3.53% |
| 2009 Q2 | 21.25 Million USD | -39.64% |
| 2009 Q1 | 35.2 Million USD | -2.02% |
| 2008 Q2 | 40.6 Million USD | -2.63% |
| 2008 Q4 | 35.93 Million USD | -9.37% |
| 2008 Q1 | 41.7 Million USD | -2.08% |
| 2008 FY | 35.93 Million USD | -15.62% |
| 2008 Q3 | 39.65 Million USD | -2.35% |
| 2007 Q3 | 43.48 Million USD | 44.86% |
| 2007 Q2 | 30.02 Million USD | -2.36% |
| 2007 Q4 | 42.58 Million USD | -2.07% |
| 2007 Q1 | 30.74 Million USD | -1.98% |
| 2007 FY | 42.58 Million USD | 35.77% |
| 2006 Q4 | 31.36 Million USD | -3.65% |
| 2006 FY | 31.36 Million USD | 198.69% |
| 2006 Q3 | 32.55 Million USD | 0.0% |
| 2005 Q4 | 10.5 Million USD | 0.0% |
| 2005 FY | 10.5 Million USD | -11.16% |
| 2004 FY | 11.82 Million USD | 0.0% |
| 2004 Q4 | 11.82 Million USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -243.29% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -683.498% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -15.119% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -877.174% |
| bluebird bio, Inc. | 224.41 Million USD | -98.958% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -1104.186% |
| Imunon, Inc. | 1.13 Million USD | -39090.972% |
| Editas Medicine, Inc. | 24.37 Million USD | -1732.02% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 96.553% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 77.399% |
| Myriad Genetics, Inc. | 130.9 Million USD | -241.1% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -72.861% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1245.042% |
| Verastem, Inc. | 40.08 Million USD | -1013.855% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 94.449% |
| Waters Corporation | 2.3 Billion USD | 80.633% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 98.574% |
| Biogen Inc. | 7.18 Billion USD | 93.788% |
| Nektar Therapeutics | 112.62 Million USD | -296.448% |
| Perrigo Company plc | 3.63 Billion USD | 87.709% |
| Dynavax Technologies Corporation | 252.41 Million USD | -76.889% |
| Illumina, Inc. | 1.48 Billion USD | 70.013% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -13686.689% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -44550.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -156.974% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -1796.852% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 24.717% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -1232.239% |
| Evolus, Inc. | 120.35 Million USD | -270.974% |
| Adicet Bio, Inc. | 17.7 Million USD | -2422.171% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -14425.049% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 83.481% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 10.975% |
| FibroGen, Inc. | 89.69 Million USD | -397.787% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 83.675% |
| OPKO Health, Inc. | 222.03 Million USD | -101.095% |
| Homology Medicines, Inc. | 43.17 Million USD | -934.139% |
| Geron Corporation | 35.05 Million USD | -1173.858% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 80.943% |
| Exelixis, Inc. | 189.94 Million USD | -135.069% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -47602.991% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -361.513% |
| Zoetis Inc. | 6.56 Billion USD | 93.198% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -150.744% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -10043.117% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 38.388% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1205.937% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 68.116% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 60.574% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 70.218% |
| Blueprint Medicines Corporation | 610.96 Million USD | 26.919% |
| Insmed Incorporated | 1.19 Billion USD | 62.584% |
| TG Therapeutics, Inc. | 100.11 Million USD | -345.974% |
| Incyte Corporation | 29.16 Million USD | -1431.102% |